low interest rates now the subject of discussion - Hey geniuses they people controlling interest rates are the ones with all the debt! Duh! If rates rise governments go broke and social services end.
sold me tires that wore out in 12,000 miles than the manager was never there when I wanted replacement.
now I won't spend any money at sears even if everything 50% off....that's my contribution to sears bankruptcy
P.T. say he ate 3 candy bars yesterday andf coke's not a bad thing because it only has as much sugar as 1 candy bar! Sorry P.T., but I don't believe you ate 3 candy bars yesterday. I'm beginning to see you as a real B.S. artist.
no science behind its trial
sears has to be the most screwed up company in the US. They are stupid and lazy. Case in point: I wanted new ignition for sears tractor part no. 163968. I go to sears web site and they tell me this part is unavailable....I go to ebay and there are 24 parts available for 163968....Sears is such a zombie company they haven't linked their web site to direct order and ship vendors who sell replacement parts for their products. The part they told me is unavailable is available..It's just unavailable on sears.com and sears isn't making any effort to capture the revenue...I paid $17 for the part....sears could have linked me to an outside vendor and sold it to me for $22.50....what a bunch of lazy bums.
that's the line being spewed on cnbc by Cramer and Co.
many small biotech companies floating stock and taking in billions of investor money, but the companies never deliver an approved drug.. Selling false hope of a miracle cure is just like junior mining companies selling the dream of a big gold strike.
We should like to analyse our experience of renal failure in association
with jaundice during the years 1956-1964 at Hammersmith Hospital.
During this period 384 patients have required dialysis treatment
for acute or acute on chronic renal failure, and of these 81, or 21% have
been jaundiced, defined as a serum bilirubin over l. 5 mg. %. A further
five patients were reported to be clinically icteric, but as the serum
bilirubin was not measured they have not been included. We have omitted
from consideration all patients with renal failure who recovered on conservative
management alone, all patients who died of their primary disease
before dialysis was considered necessary, or who died before dialysis could
be undertaken. Thus we are only considering here a group of patients
with severe renal failure whose blood ureas all exceeded 350 mg. % at
some point in their illness.
The 81 patients have been subdivided into 12 groups depending on
the predominant aetiology of the jaundice ( Table I ). There is some degree
of overlap in the groups as there may be mild haemolysis in some obstetric
patients, and infection was obviously present in some patients with obstructive
the sec and us attorney should take a close look at sarepta....preying on the most vulnerable group of pediatric patients to make millions,,,,a 12 person study?
ARAMCO going to buy MPC and all the other refiners after their $2T IPO. Then they will unveil the new technology of converting water to wine.
Miravirsen is a mir-122 inhibitor similar in principal to Rg-101 that was also being developed in San Diego....Roche bought Sabtaris for $485M......At this point I think one of the big biotechs should step in and pick up RGLS on the cheap.
I just read the BostonBiz article on SRPT. The problem with the article is it didn't mention SRPT's clinical data is based on very few participants. In the 201 trial only 6 individuals got the drug and and 12 received it in the 202 trial. The drugs efficacy is questionable. I quote from the FDA briefing document: "Figure 2 shows the change over time in NSAA scores for all 12 eteplirsen-treated patients in Study 201/202. All show progressive declines in NSAA scores, with six patients moving to NSAA scores that have been reported to be associated with being within one year of loss of 1 Mazzone E, Martinelli D, Berardinelli A, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010; 20:712–16. ambulation, and an additional four patients moving to scores associated with being within 2 years from loss of ambulation."
As an investor I see too much risk and uncertainty in this stock. If I had to wager I'd bet on non-approval. The SRPT story reminds me of Dendreon back in 2007 when people campaigned for the approval of its drug. From the little I know, SRPT looks suspect.